MedTrace Logo

Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)

NCT04923984 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-02-03

No results posted yet for this study

Summary

EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH.

Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.

Conditions

  • Subdural Hematoma

Interventions

PROCEDURE

Embolization of the middle meningeal artery

embolization of the middle meningeal artery with an embolic agent (Microparticles, liquid embolic agents, SwiftPAC coils or others).

Sponsors & Collaborators

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Jai Shankar, MD · University of Manitoba

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Canada

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923984 on ClinicalTrials.gov